Pharvaris BV (PHVS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $2.36B
Last updated: Nov 17, 2026 at 11:06 AM ET
Pharvaris BV (PHVS) Financials: Revenue, Profit and Cash Flow
Pharvaris BV reported revenue of EUR 0 for the fiscal year ended Dec 31, 2025. That year, net income was EUR -175.70M, operating cash flow was EUR -137.07M and free cash flow was EUR -137.24M. The quarter ended Sep 30, 2026 had revenue of EUR 0 and net income of EUR -47.41M.
Revenue and Margins
The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of EUR 169.82M.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | 0 | N/A | N/A | N/A | N/A |
| Dec 2024 | 0 | N/A | N/A | N/A | N/A |
| Dec 2023 | 0 | N/A | N/A | N/A | N/A |
| Dec 2022 | 0 | N/A | N/A | N/A | N/A |
| Dec 2021 | 0 | N/A | N/A | N/A | N/A |
| Dec 2020 | 0 | N/A | N/A | N/A | N/A |
| Dec 2019 | 0 | N/A | N/A | N/A | N/A |
| Dec 2018 | 0 | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
| Cost of revenue | N/A | N/A | 252.27K | 150.19K | 80.46K | N/A | N/A | N/A |
| Gross profit | N/A | N/A | -252.27K | -150.19K | -80.46K | N/A | N/A | N/A |
| Research and development | 124.48M | 98.56M | 65.58M | 57.38M | 35.79M | 22.24M | 6.36M | 3.65M |
| Operating income | -169.82M | -145.69M | -96.91M | -86.71M | -54.14M | -28.51M | -8.97M | -4.31M |
| Net income | -175.70M | -134.22M | -100.88M | -76.33M | -42.73M | -29.62M | -8.98M | -4.31M |
| EBITDA | N/A | -145.42M | N/A | -86.56M | -42.31M | N/A | N/A | N/A |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit | N/A | -182.27K | -106.45K | N/A | N/A | N/A | -97.02K | N/A | N/A | -69.02K | -71.00K | N/A |
| Operating income | -50.08M | -50.79M | -45.00M | -47.60M | -39.66M | -40.37M | 42.19M | -45.09M | -37.90M | -34.38M | -28.31M | -27.18M |
| Net income | -47.41M | -47.84M | -39.85M | -46.74M | -37.14M | -45.48M | -46.34M | -34.76M | -41.71M | -29.73M | -28.02M | -32.75M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded short-term debt of EUR 200.21K by 291.48M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | 301.45M | 291.37M | 398.69M | 167.73M | 212.09M | 101.10M | 20.60M | 5.43M | 4.80M |
| Current assets | 299.17M | 289.42M | 397.85M | 166.85M | 211.57M | 100.95M | 20.58M | 5.43M | 4.80M |
| Cash and equivalents | 291.68M | 280.73M | 391.23M | 161.84M | 209.35M | 98.63M | 20.33M | 5.39M | 4.80M |
| Total liabilities | 30.18M | 23.61M | 14.65M | 18.47M | 7.14M | 5.31M | 1.92M | 481.34K | 138.84K |
| Short-term debt | 200.21K | 222.43K | 195.34K | 187.40K | 99.43K | N/A | N/A | N/A | N/A |
| Shareholder equity | 271.27M | 267.76M | 384.05M | 149.26M | 204.95M | 95.79M | 18.67M | 4.95M | 4.66M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 295.06M | 328.67M | 259.79M | 301.45M | 338.90M | 209.81M | 248.06M | 291.37M | 313.18M | 351.85M | 377.60M | 398.69M |
| Total liabilities | 30.09M | 27.86M | 23.46M | 30.18M | 26.66M | 25.47M | 22.73M | 23.61M | 16.39M | 19.08M | 18.43M | 14.65M |
| Cash and equivalents | 282.73M | 318.28M | 246.96M | 291.68M | 329.29M | 199.57M | 236.50M | 280.73M | 305.19M | 343.57M | 368.34M | 391.23M |
| Shareholder equity | 264.97M | 300.81M | 236.33M | 271.27M | 312.24M | 184.34M | 225.34M | 267.76M | 296.79M | 332.77M | 359.17M | 384.05M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -137.07M | -120.13M | -93.05M | -67.16M | -44.60M | -21.50M | -6.68M | -3.92M |
| Capital expenditures | 164.62K | 538.09K | 89.98K | 124.30K | 130.03K | 42.98K | 13.48K | 13.48K |
| Free cash flow | -137.24M | -120.67M | -93.14M | -67.29M | -44.73M | -21.54M | -6.69M | -3.93M |
| Investing cash flow | -164.62K | -538.09K | -89.98K | -124.30K | -130.03K | -42.98K | -13.48K | -13.48K |
| Financing cash flow | 160.61M | 2.68M | 325.39M | 8.65M | 143.67M | 101.20M | 21.63M | 4.51M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -42.22M | -37.80M | -49.57M | -37.95M | -30.67M | -29.98M | -38.47M | -34.95M | -33.26M | -27.68M | -24.23M | -23.81M |
| Capital expenditures | 0 | 26.91K | 52.95K | 1.54K | 18.71K | 16.64K | 161.00K | 160.92K | 306.32K | 40.14K | 30.71K | 28.38K |
| Free cash flow | -42.22M | -37.83M | -49.62M | -37.95M | -30.69M | -30.00M | -38.63M | -35.11M | -33.57M | -27.72M | -24.26M | -23.84M |
Frequently Asked Questions About PHVS
What is Pharvaris BV's annual revenue?
Pharvaris BV reported revenue of EUR 0 for the fiscal year ended Dec 31, 2025.
Is Pharvaris BV profitable?
No. Pharvaris BV reported net income of EUR -175.70M for the fiscal year ended Dec 31, 2025.
How much free cash flow does PHVS generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of EUR -137.07M minus capital expenditures of EUR 164.62K produced free cash flow of EUR -137.24M.
How much debt does Pharvaris BV have?
The balance sheet dated Dec 31, 2025 reported short-term debt of EUR 200.21K and cash and equivalents of EUR 291.68M.
PHVS pages: Overview, Financials, Competitors